成人急性淋巴细胞白血病分子生物学改变与临床治疗及预后关系的初步研究  

A Preliminary Study on the Relationship Between Molecular Abnormality and Clinical Features in Adult Acute Lymphoblastic Leukemia

作　　者：许家仁[1] 朱广荣[1] 陈丽娟[1] 

机构地区：[1]南京医科大学第一附属医院血液科

出　　处：《南京医科大学学报（自然科学版）》1997年第4期351-353,共3页Journal of Nanjing Medical University(Natural Sciences)

摘　　要：应用多聚酶链反应技术检测了１４例急性淋巴细胞白血病（ＡＬＬ）患者的ｂｃｒ／ａｂｌ融合基因、ＴＣＲγ基因重排及ＩｇＨ基因重排，结果发现，ｂｃｒ／ａｂｌ融合基因阳性５例，阳性率３５．７％，其中４例为Ｂ－ＡＬＬ，１例ＴＣＲγ及ＩｇＨ基因重排均阴性。ｂｃｒ／ａｂｌ（＋）患者与ｂｃｒ／ａｂｌ（－）患者在临床表现方面无显著性差异，但ｂｃｒ／ａｂｌ（＋）患者治疗效果比ｂｃｒ／ａｂｌ（－）患者差。BCR/ABL fusion transcripts and IgH TCR γ gene rearrangement in 14 patients with acute lymphoblastic leukemia was detected using the polymerase chain reaction. The results showed that 5 cases (35.7%) were found to be BCR/ABL positive. Among them, 4 cases were B ALL and the other was without expression of IgH and TCR γ gene rearrangement. The two groups of patients with BCR/ABL positive and negative ALL did not differ in clinical manifestation, but the outcome of the former is bad and less responsive to chemotherapy.

关 键 词：白血病 CML 治疗 预后 成人 分子生物学 

分 类 号：R733.710.5[医药卫生—肿瘤]